Scope, Claims, and US Patent Landscape for US Drug Patent 10,478,574
What does US 10,478,574 claim at a technical level?
US 10,478,574 is a nasal delivery method claim set anchored to a mouthpiece-nosepiece system and a biofluid-mechanics trigger: the patient exhales through the mouthpiece to create an exhalation air flow that enters the nose and enables deposition of a pharmaceutical dose at a targeted anatomical region.
All independent claims are structurally similar and differ primarily in deposition fraction thresholds (30%, 40%, 50%) and the timing qualification “during a time when” the exhalation airflow exceeds a predetermined flow rate.
Core method architecture (present across independent claims 1, 14, 27)
Each independent claim requires these elements in combination:
- Mouthpiece fit: “fitting a mouthpiece to a mouth of the subject.”
- Nosepiece fit: “fitting a nosepiece unit to a first nostril of the subject,” where the nosepiece unit includes:
- Nosepiece configured “to guide the nosepiece unit into a first nasal passageway.”
- Delivery channel fluidly connected between mouthpiece and nosepiece so that exhalation airflow is delivered from mouthpiece through the channel and through the nosepiece during exhalation.
- Supply unit configured to “deliver a dose of the pharmaceutical composition.”
- Trigger maneuver:
- Subject exhales through the mouthpiece.
- Exhalation is sufficient to cause closure of an oropharyngeal velum.
- Airflow path qualification:
- Exhalation airflow exceeds a predetermined flow rate.
- Airflow passes through the first nostril into a first nasal passageway.
- Flow routes “around a posterior margin of a nasal septum” and then into a second nasal passageway and out a second nostril.
- Targeting/deposition constraint (the differentiator among independent claims):
- During the exhalation airflow window, the dose is deposited such that at least X% (30% in claim 1; 40% in claim 14; 50% in claim 27) of the dose “as initially deposited” is deposited at an:
- “upper posterior region of the nasal airway”
- “posterior of a nasal valve”
- “above an inferior meatus.”
Independent claims: deposition fraction carve-outs
| Claim |
Deposition threshold required |
Anatomical target wording (same across all independents) |
Timing qualifier |
| 1 |
≥ 30% |
Upper posterior nasal airway; posterior of nasal valve; above inferior meatus |
“during a time when” exhalation airflow is above predetermined flow rate |
| 14 |
≥ 40% |
Same |
Same |
| 27 |
≥ 50% |
Same |
Same |
What the dependent claims add (composition scope)
The dependent claims primarily define pharmaceutical composition classes and delivery format.
Delivery format limitations
- Aerosol spray (claims 2, 15, 28)
- Aerosol is limited further to liquid (claims 3, 16, 29) or powder (claims 4, 17, 30).
- Liquid jet (claims 5, 18, 31)
Drug/class limitations
- Dopamine agonist (claims 6, 19, 32)
- Triptan (claims 7, 20, 33) with sumatriptan specifically claimed (claims 8, 21, 34)
- “Activity on a learning pathway” (claims 9, 22, 35)
- Vasopressin or pharmaceutically acceptable derivatives/analogues (claims 10, 23, 36)
- Desmopressin or pharmaceutically acceptable derivatives/analogues (claims 11, 24, 37)
- Acetylcholinesterase inhibitor (claims 12, 25, 38) with rivastigmine specifically claimed (claims 13, 26, 39)
What is the enforceable claim “scope” in practice?
Enforcement is easiest where an accused system matches the combination of:
1) Mouthpiece + nosepiece delivery channel architecture
2) Patient-exhalation driven flow through that channel
3) Oropharyngeal velum closure during exhalation
4) Airflow exceeds a predetermined flow rate
5) Posterior septum routing through nasal passages and discharge via the other nostril
6) Dose deposition at an upper posterior region quantified as ≥30%, ≥40%, or ≥50% depending on the independent claim
Key scope-critical terms
These are the claim levers most likely to narrow real-world embodiments:
- “Exhalation breath … to cause closure of an oropharyngeal velum”
This is not a generic nasal delivery method. It ties deposition performance to a functional maneuver and physiological closure state.
- “Exhalation air flow … exceeds a predetermined flow rate”
“Predetermined” implies a threshold defined for the method; it also gates “during a time when” deposition is measured.
- “Flows … around a posterior margin of a nasal septum … and into a second nasal passageway … and out of a second nostril”
This is an airflow path constraint, not just a “nasal delivery” constraint.
- “Upper posterior region … posterior of a nasal valve … above an inferior meatus”
This is an anatomical deposition region constraint; it implies deposition measurement methodology and target definition.
- “At least X% of the dose … as initially deposited”
The phrase “as initially deposited” suggests a baseline dose quantification method; the numeric fraction is the core infringement switch.
How broad are claims across drug types?
The dependent claims list multiple drug categories, but the independent claims are written to cover a “pharmaceutical composition” generally, then narrow via dependent claim dependencies.
Drug coverage map from the dependent claims
| Dependency |
Covered drug types explicitly listed |
| Dopamine agonists |
dopamine agonist (independent-claim dependent: 6/19/32) |
| Triptans |
triptan (7/20/33) including sumatriptan (8/21/34) |
| “Learning pathway” activity |
“pharmaceutical composition has activity on a learning pathway” (9/22/35) |
| Vasopressin family |
vasopressin/derivatives/analogs (10/23/36) |
| Desmopressin family |
desmopressin/derivatives/analogs (11/24/37) |
| Cholinesterase inhibitors |
acetylcholinesterase inhibitor (12/25/38) including rivastigmine (13/26/39) |
Practical impact on competitor design
- If a competitor uses the same device mechanics (exhalation through mouthpiece, velum closure, airflow path, deposition region), then swapping among listed drug types can land them directly into dependent claim scope.
- If a competitor uses the same device and deposition performance but uses a non-listed drug, they may still risk coverage under the independent method claims, unless the patent’s validity in prosecution or claim interpretation relies on the dependent list’s contextual narrowing (not provided here).
What does the method requirement imply for respiratory mechanics devices?
The claim set reads like a procedurally controlled nasal deposition method rather than a passive nasal spray.
The system is essentially:
- patient performs exhalation via mouthpiece,
- nasal airflow is guided by a nosepiece into the nasal passage,
- velum closure converts exhalation into a directed nasal airflow path,
- dose is delivered during that airflow window so that deposition shifts to an upper posterior site.
This design targets deposition beyond conventional anterior/nasal valve areas.
How do the three independent claims differ for freedom-to-operate?
The independent claims create three performance tiers:
- Claim 1: ≥30% deposition at upper posterior region
- Claim 14: ≥40%
- Claim 27: ≥50%
If a competitor’s system achieves lower deposition (for example, 25%), they would not meet any of the three deposition thresholds as written.
If a competitor can show deposition at, say, 42%, then:
- they can land within claim 14 and claim 1, but not necessarily claim 27.
- infringement will turn on quantification method, “initially deposited” baseline, and the measurement “during the time” the flow is above predetermined threshold.
Claim-by-claim scope summary (US 10,478,574)
Independent claims
- Claim 1: exhalation-through-mouthpiece + nosepiece airflow + velum closure + airflow > predetermined rate + posterior septum routing + dose deposited with ≥30% to upper posterior region (posterior to nasal valve; above inferior meatus).
- Claim 14: same method, but ≥40% deposition.
- Claim 27: same method, but ≥50% deposition.
Dependent claims
- Claims 2-4 / 15-17 / 28-30: aerosol spray, liquid or powder
- Claims 5 / 18 / 31: liquid jet
- Claims 6 / 19 / 32: dopamine agonist
- Claims 7-8 / 20-21 / 33-34: triptan including sumatriptan
- Claims 9 / 22 / 35: learning pathway activity
- Claims 10-11 / 23-24 / 36-37: vasopressin / desmopressin families (derivatives/analogs)
- Claims 12-13 / 25-26 / 38-39: acetylcholinesterase inhibitor including rivastigmine
Patent landscape: what else is likely out there and how does this claim set position?
The prompt does not provide the publication number, assignee, filing date, patent family members, cited references, or prosecution history for US 10,478,574. Without those, a complete, accurate US landscape map (overlapping patents by assignee/technology) cannot be produced.
What can be inferred from claim structure alone
This patent’s claim set targets a combination of three technology buckets that typically appear in separate prior art groups:
1) Exhalation-driven or patient-controlled nasal delivery systems (device mechanics + mouth/nose interfaces + airflow direction)
2) Anatomically targeted nasal deposition (upper posterior region deposition, septum-posterior routing, nasal valve and inferior meatus references)
3) Therapeutic nasal formulations (for dopamine agonists, triptans/sumatriptan, vasopressin/desmopressin, acetylcholinesterase inhibitors such as rivastigmine; plus aerosol vs liquid jet formats)
From an infringement-defense perspective, prior art that exists in any one bucket may not defeat the combination if it lacks the other two. Here, the critical novelty appears to be the closed-velum exhalation airflow path plus measured posterior deposition fraction.
Practical diligence checklist (what investors and R&D teams test against)
Even without knowing assignee or family, the claims define measurable criteria that can be validated in development and during competitive benchmarking:
- Deposition quantification
- Measure percentage of initially deposited dose at the “upper posterior region” defined as posterior to nasal valve and above inferior meatus.
- Demonstrate deposition during the exhalation window when flow rate exceeds predetermined threshold.
- Airflow mapping
- Verify routing “around a posterior margin of a nasal septum” with airflow exiting through second nostril.
- Physiology trigger
- Confirm exhalation “cause closure of an oropharyngeal velum” (objective proxy measures may be required).
- Device configuration
- Confirm mouthpiece to nosepiece delivery channel and nosepiece guiding into the nasal passageway.
- Formulation format
- Confirm aerosol spray (liquid/powder) or liquid jet delivery is used.
- Drug scope
- Confirm whether the therapeutic fits the explicit categories in dependent claims (or assess independent claim risk based on the general “pharmaceutical composition”).
Key Takeaways
- US 10,478,574 claims a patient-exhalation-driven nasal delivery method using a mouthpiece and nosepiece, with oropharyngeal velum closure, flow-rate gating, and posterior nasal septum routing.
- The enforceable differentiator is measured dose deposition into the upper posterior nasal airway with numeric thresholds of ≥30%, ≥40%, or ≥50% across independent claims 1, 14, and 27.
- Dependent claims cover aerosol spray (liquid or powder) and liquid jet formats, plus multiple therapeutic classes including dopamine agonists, triptans/sumatriptan, vasopressin/desmopressin, and acetylcholinesterase inhibitors/rivastigmine.
- A valid competition/clearance assessment must test the exact deposition fraction and anatomical target definition, not just general nasal delivery.
FAQs
1) What is the single most important infringement criterion in US 10,478,574?
The method requires quantified deposition of “at least X%” of the initially deposited dose in an upper posterior nasal region (X = 30, 40, or 50 depending on the independent claim).
2) Does the patent require specific drugs in the independent claims?
No. Independent claims cover a “pharmaceutical composition” generally. Specific drug classes are added in dependent claims.
3) How do the three independent claims differ?
They are the same method framework but impose different deposition fraction thresholds: ≥30% (claim 1), ≥40% (claim 14), and ≥50% (claim 27).
4) Is aerosol spray versus liquid jet required?
Not for the independent claims. Dependent claims specifically limit to aerosol spray (liquid/powder) or liquid jet.
5) What device mechanics are required?
A mouthpiece fitted to the mouth, a nosepiece unit fitted to a nostril, and a delivery channel connecting the two so that exhalation airflow travels through the channel and nosepiece during exhalation.
References
- United States Patent No. 10,478,574.
